Announcements Trials
Browse Landscape

Phase

Phase 2 22Phase 1 10Phase 3 4Phase 1/2 2Phase NA 1

Status

Completed 4Recruiting 2Withdrawn 1Unknown 1Terminated 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4

Conditions

Prostatic Neoplasms 3Hormone Refractory Prostate Cancer 1

Interventions

Cyclophosphamide 299Cisplatin 298Paclitaxel 257Radiotherapy 255Fluorouracil 234Carboplatin 234Docetaxel 230Doxorubicin 216Dexamethasone 166Gemcitabine 156Vincristine 147Etoposide 136Leucovorin 133Capecitabine 129Bevacizumab 129Prednisone 125Rituximab 118Methotrexate 118Cytarabine 110Filgrastim 99Trastuzumab 97Oxaliplatin 96pembrolizumab 83Pemetrexed 73Epirubicin 70Tamoxifen 69Drug Therapy 69Irinotecan 65Granulocyte Colony-Stimulating Factor 60Daunorubicin 58

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 3 × Completed × radium Ra 223 dichloride × Clear all
NCT00699751 2026-02-23

ALSYMPCA

Bayer

Phase 3 Completed
921 enrolled 43 charts
Genitourinary

Hormone Refractory Prostate Cancer

NCT02043678 2025-02-19

ERA 223

Bayer

Phase 3 Completed
806 enrolled 32 charts
Genitourinary

Prostatic Neoplasms

NCT01810770 2018-09-19

Radium-223 Dichloride Asian Population Study in the Treatment of CRPC Patients With Bone Metastasis

Bayer

Phase 3 Completed
243 enrolled
Genitourinary

Prostatic Neoplasms

NCT01618370 2017-03-31

Radium(223) Dichloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases

Bayer

Phase 3 Completed
705 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡